Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Physiol Endocrinol Metab ; 316(4): E590-E604, 2019 04 01.
Article in English | MEDLINE | ID: mdl-30668150

ABSTRACT

Parathyroid hormone (PTH) and its related peptide (PTH-related peptide 1-34) are two of the Food and Drug Administration-approved bone-promoting drugs for age-related osteoporosis. Treatment with PTH stimulates bone formation. However, the molecular mechanisms of PTH-mediated osteoblast differentiation and cell proliferation are still not completely understood. In this study, we showed that PTH induced endoplasmic reticulum (ER) stress in osteoblasts through the PKR-like endoplasmic reticulum kinase (PERK)-eukaryotic initiation factor 2α (EIF2α)-activating transcription factor 4 (ATF4)-signaling pathway. After separately blocking PERK-EIF2α-ATF4 signaling with two different inhibitors [AMG'44 and integrated stress response inhibitor (ISRIB)] or specific small interfering RNA for PERK and ATF4, the following targets were all downregulated: expression of osteoblast differentiation markers [runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), type I collagen (Col1a1), and osteocalcin (Ocn)], cell proliferation markers (CyclinE, CyclinD, and CDC2), amino acid import (Glyt1), and metabolism-related genes (Asns). Additionally, Alp-positive staining cells, Alp activity, matrix mineralization, Ocn secretion, and cell proliferation indexes were inhibited. Interestingly, we found that salubrinal enhanced PTH-induced osteoblast differentiation and proliferation by maintenance of phosphorylation of EIF2α. Furthermore, we observed that PTH increased the association between heat shock protein 90 (HSP90) and PERK and maintained PERK protein stabilization in the early stages of PTH-induced ER stress. Treatment of MC3T3-E1 cells with geldanamycin, an HSP90 inhibitor, decreased PERK protein expression and inhibited osteoblast differentiation and cell proliferation upon PTH treatment. Taken together, our data demonstrate that PTH regulates osteoblast differentiation and cell proliferation, partly by activating the HSP90-dependent PERK-EIF2α-ATF4 signaling pathway.


Subject(s)
Cell Differentiation/drug effects , Cell Proliferation/drug effects , Endoplasmic Reticulum Stress/drug effects , Osteoblasts/drug effects , Parathyroid Hormone/pharmacology , Activating Transcription Factor 4/metabolism , Alkaline Phosphatase/drug effects , Alkaline Phosphatase/metabolism , Animals , Benzoquinones/pharmacology , CDC2 Protein Kinase/drug effects , CDC2 Protein Kinase/metabolism , Cell Line , Collagen Type I/drug effects , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Core Binding Factor Alpha 1 Subunit/drug effects , Core Binding Factor Alpha 1 Subunit/metabolism , Cyclin D/drug effects , Cyclin D/metabolism , Cyclin E/drug effects , Cyclin E/metabolism , Enzyme Inhibitors/pharmacology , Eukaryotic Initiation Factor-2/metabolism , Glycine Plasma Membrane Transport Proteins/drug effects , Glycine Plasma Membrane Transport Proteins/metabolism , HSP90 Heat-Shock Proteins/antagonists & inhibitors , HSP90 Heat-Shock Proteins/drug effects , HSP90 Heat-Shock Proteins/metabolism , Lactams, Macrocyclic/pharmacology , Mice , Osteoblasts/metabolism , Osteocalcin/drug effects , Osteocalcin/metabolism , Signal Transduction , eIF-2 Kinase/metabolism
2.
Oncol Rep ; 32(4): 1670-80, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25109257

ABSTRACT

Substantial evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have potential as chemopreventative/therapeutic agents. However, these agents cannot be universally recommended for prevention purposes due to their potential side-effect profiles. Here, we compared the growth inhibitory and mechanistic activity of aspirin to two novel analogues, diaspirin (DiA) and fumaryl diaspirin (F-DiA). We found that the aspirin analogues inhibited cell proliferation and induced apoptosis of colorectal cancer cells at significantly lower doses than aspirin. Similar to aspirin, we found that an early response to the analogues was a reduction in levels of cyclin D1 and stimulation of the NF-κB pathway. This stimulation was associated with a significant reduction in basal levels of NF-κB transcriptional activity, in keeping with previous data for aspirin. However, in contrast to aspirin, DiA and F-DiA activity was not associated with nucleolar accumulation of RelA. For all assays, F-DiA had a more rapid and significant effect than DiA, identifying this agent as particularly active against colorectal cancer. Using a syngeneic colorectal tumour model in mice, we found that, while both agents significantly inhibited tumour growth in vivo, this effect was particularly pronounced for F-DiA. These data identify two compounds that are active against colorectal cancer in vitro and in vivo. They also identify a potential mechanism of action of these agents and shed light on the chemical structures that may be important for the antitumour effects of aspirin.


Subject(s)
Adenocarcinoma , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Aspirin/analogs & derivatives , Cell Proliferation/drug effects , Colorectal Neoplasms , NF-kappa B/drug effects , Signal Transduction/drug effects , Animals , Aspirin/pharmacology , Cell Cycle/drug effects , Cell Line, Tumor , Cyclin D/drug effects , Cyclin D/metabolism , Drug Screening Assays, Antitumor , Humans , Mice , Mice, Nude , NF-kappa B/metabolism , Transcription Factor RelA/drug effects , Transcription Factor RelA/metabolism , Xenograft Model Antitumor Assays
3.
J Oral Pathol Med ; 42(4): 332-8, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23106397

ABSTRACT

BACKGROUND: Although oral squamous cell carcinomas (OSCCs) commonly overexpress the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) exhibit poor efficacy clinically. Activation of the insulin-like growth factor-1 receptor (IGF1R) induces resistance of OSCC cells to EGFR-TKIs in vitro. This study seeks to evaluate the changes in cell cycle status in OSCC cells in response to gefitinib and IGF1R activation. METHODS: SCC-25 OSCC cells were used for in vitro analyses. RESULTS: Gefitinib caused a 50% reduction in S-phase population, and IGF1R activation caused a 2.8-fold increase; combined treatment yielded a baseline S-phase population. Gefitinib treatment increased the cyclin-dependent kinase inhibitor p27, and this was not abrogated by IGF1R activation. pT157-p27 was noted by immunoblot to be decreased on gefitinib treatment, but this was reversed with IGF1R activation. T157 phosphorylation contributes to cytoplasmic localization of p27 where it can promote cell proliferation and cell motility. Using both subcellular fractionation and immunofluorescence microscopy techniques, IGF1R stimulation was noted to increase the relative cytoplasmic localization of p27; this persisted when combined with gefitinib. CONCLUSIONS: IGF1R activation partially reverses the cell cycle arrest caused by gefitinib in OSCC cells. While IGF1R stimulation does not eliminate the gefitinib-induced increase in total p27, its phosphorylation state and subcellular localization are altered. This may contribute to the ability of the IGF1R to rescue OSCC cells from EGFR-TKI treatment and may have important implications for the use of p27 as a biomarker of cell cycle arrest and response to therapy.


Subject(s)
Carcinoma, Squamous Cell/pathology , Cyclin-Dependent Kinase Inhibitor p27/physiology , ErbB Receptors/physiology , Mouth Neoplasms/pathology , Protein Kinase Inhibitors/pharmacology , Quinazolines/pharmacology , Receptor, IGF Type 1/physiology , Cell Cycle/drug effects , Cell Line, Tumor , Cell Nucleus/ultrastructure , Cyclin D/drug effects , Cyclin-Dependent Kinase Inhibitor p27/drug effects , Cytoplasm/ultrastructure , Dose-Response Relationship, Drug , Drug Resistance, Neoplasm , ErbB Receptors/antagonists & inhibitors , Gefitinib , Humans , Insulin-Like Growth Factor I/pharmacology , Oncogene Protein v-akt/physiology , Peptide Fragments/pharmacology , Phosphorylation , Protein Kinase Inhibitors/administration & dosage , Pyrimidines/pharmacology , Quinazolines/administration & dosage , Receptor, IGF Type 1/drug effects , S Phase/drug effects , Subcellular Fractions/ultrastructure
4.
Br J Cancer ; 107(12): 1978-86, 2012 Dec 04.
Article in English | MEDLINE | ID: mdl-23169291

ABSTRACT

BACKGROUND: Activins control the growth of several tumour types including thoracic malignancies. In the present study, we investigated their expression and function in malignant pleural mesothelioma (MPM). METHODS: The expression of activins and activin receptors was analysed by quantitative PCR in a panel of MPM cell lines. Activin A expression was further analysed by immunohistochemistry in MPM tissue specimens (N=53). Subsequently, MPM cells were treated with activin A, activin receptor inhibitors or activin-targeting siRNA and the impact on cell viability, proliferation, migration and signalling was assessed. RESULTS: Concomitant expression of activin subunits and receptors was found in all cell lines, and activin A was overexpressed in most cell lines compared with non-malignant mesothelial cells. Similarly, immunohistochemistry demonstrated intense staining of tumour cells for activin A in a subset of patients. Treatment with activin A induced SMAD2 phosphorylation and stimulated clonogenic growth of mesothelioma cells. In contrast, treatment with kinase inhibitors of activin receptors (SB-431542, A-8301) inhibited MPM cell viability, clonogenicity and migration. Silencing of activin A expression by siRNA oligonucleotides further confirmed these results and led to reduced cyclin D1/3 expression. CONCLUSION: Our study suggests that activin A contributes to the malignant phenotype of MPM cells via regulation of cyclin D and may represent a valuable candidate for therapeutic interference.


Subject(s)
Activins/antagonists & inhibitors , Antineoplastic Agents/pharmacology , Cyclin D/metabolism , Mesothelioma/metabolism , Mesothelioma/pathology , Pleural Neoplasms/metabolism , Pleural Neoplasms/pathology , Blotting, Western , Cell Movement , Cell Proliferation , Cell Survival , Cyclin D/drug effects , Gene Expression Regulation, Neoplastic , Gene Silencing , Humans , Immunohistochemistry , Mesothelioma/drug therapy , Phenotype , Phosphorylation/drug effects , Pleural Neoplasms/drug therapy , RNA, Small Interfering/pharmacology , Real-Time Polymerase Chain Reaction , Signal Transduction/drug effects , Smad2 Protein/metabolism , Tumor Stem Cell Assay , Up-Regulation
5.
J Exp Ther Oncol ; 9(3): 175-81, 2011.
Article in English | MEDLINE | ID: mdl-22070048

ABSTRACT

Ovarian cancer is the leading cause of death from gynecological cancer. The high mortality rate reflets the lack of early diagnosis and limited treatment alternatives. We have observed a number of properties of zinc cytotoxicity that make it attractive from a therapeutic standpoint. Using SKOV3 and ES2 cells, ovarian cancer cell lines that demonstrate varied degrees of resistance to known therapeutics, we show that zinc killing is time and concentration dependent. Death is preceded by distinct changes in cell shape and size. The effects of zinc are additive with cisplatin or doxorubicin, whose morphological effects are distinct from those of zinc. Cytotoxicity of paclitaxel is minimal, making it difficult to determine additivity with zinc. Paclitaxel results in changes in cell shape and size similar to those of zinc but has different effects on cell cycle progression and cyclin expression. The data indicate that the means by which zinc kills ovarian cancer cells is distinct from currently used chemotherapeutics. Based on the properties reported here, zinc has the potential to be developed as either a primary treatment or as a second line of defense against cancers that have developed resistance to currently used chemotherapeutics.


Subject(s)
Cell Cycle Checkpoints/drug effects , Ovarian Neoplasms/drug therapy , Trace Elements/pharmacology , Zinc/pharmacology , Antibiotics, Antineoplastic/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Cell Death/drug effects , Cell Line, Tumor , Cisplatin/pharmacology , Cyclin A/drug effects , Cyclin A/metabolism , Cyclin D/drug effects , Cyclin D/metabolism , Cyclin E/drug effects , Cyclin E/metabolism , Dose-Response Relationship, Drug , Doxorubicin/pharmacology , Drug Synergism , Female , Humans , Paclitaxel/pharmacology , Pyridines/pharmacology , Thiones/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...